SAB Biotherapeutics Statistics
Total Valuation
SABS has a market cap or net worth of $245.26 million. The enterprise value is $140.53 million.
Important Dates
The last earnings date was Tuesday, May 12, 2026, before market open.
| Earnings Date | May 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
SABS has 70.28 million shares outstanding. The number of shares has increased by 227.56% in one year.
| Current Share Class | 70.28M |
| Shares Outstanding | 70.28M |
| Shares Change (YoY) | +227.56% |
| Shares Change (QoQ) | +11.59% |
| Owned by Insiders (%) | 2.69% |
| Owned by Institutions (%) | 44.20% |
| Float | 29.95M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.15 |
| P/TBV Ratio | 1.06 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.45, with a Debt / Equity ratio of 0.03.
| Current Ratio | 11.45 |
| Quick Ratio | 11.06 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -248.79 |
Financial Efficiency
Return on equity (ROE) is -0.32% and return on invested capital (ROIC) is -27.80%.
| Return on Equity (ROE) | -0.32% |
| Return on Assets (ROA) | -25.38% |
| Return on Invested Capital (ROIC) | -27.80% |
| Return on Capital Employed (ROCE) | -24.38% |
| Weighted Average Cost of Capital (WACC) | 7.17% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$109,428 |
| Employee Count | 86 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +80.83% in the last 52 weeks. The beta is 0.55, so SABS's price volatility has been lower than the market average.
| Beta (5Y) | 0.55 |
| 52-Week Price Change | +80.83% |
| 50-Day Moving Average | 3.76 |
| 200-Day Moving Average | 3.43 |
| Relative Strength Index (RSI) | 43.36 |
| Average Volume (20 Days) | 1,029,460 |
Short Selling Information
The latest short interest is 2.75 million, so 3.91% of the outstanding shares have been sold short.
| Short Interest | 2.75M |
| Short Previous Month | 2.42M |
| Short % of Shares Out | 3.91% |
| Short % of Float | 9.17% |
| Short Ratio (days to cover) | 2.76 |
Income Statement
| Revenue | n/a |
| Gross Profit | -33.35M |
| Operating Income | -58.18M |
| Pretax Income | -398,429 |
| Net Income | -9.41M |
| EBITDA | -55.12M |
| EBIT | -58.18M |
| Earnings Per Share (EPS) | -$2.05 |
Full Income StatementBalance Sheet
The company has $107.39 million in cash and $6.17 million in debt, with a net cash position of $101.22 million or $1.44 per share.
| Cash & Cash Equivalents | 107.39M |
| Total Debt | 6.17M |
| Net Cash | 101.22M |
| Net Cash Per Share | $1.44 |
| Equity (Book Value) | 227.25M |
| Book Value Per Share | 3.00 |
| Working Capital | 102.93M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$51.25 million and capital expenditures -$1.92 million, giving a free cash flow of -$53.17 million.
| Operating Cash Flow | -51.25M |
| Capital Expenditures | -1.92M |
| Depreciation & Amortization | 3.06M |
| Net Borrowing | -283,887 |
| Free Cash Flow | -53.17M |
| FCF Per Share | -$0.76 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
SABS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -227.56% |
| Shareholder Yield | -227.56% |
| Earnings Yield | -3.89% |
| FCF Yield | -21.99% |
Analyst Forecast
The average price target for SABS is $10.10, which is 189.40% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $10.10 |
| Price Target Difference | 189.40% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 5, 2024. It was a reverse split with a ratio of 1:10.
| Last Split Date | Jan 5, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
